Altimmune 주식 주식분석 | 주식가격 | 뉴스 | ALT | US02155H2004 | A2N5Z6 | 2025년 7월

날짜	Altimmune 주식 가격
	4.08 undefined
	4.09 undefined
	4.15 undefined
	4.28 undefined
	4.17 undefined
	4.08 undefined
	4.07 undefined
	4.11 undefined
	4.06 undefined
	4.16 undefined
	4.16 undefined
	4.22 undefined
	4.16 undefined
	4.16 undefined
	4.42 undefined
	4.74 undefined
	4.53 undefined
	4.43 undefined
	4.74 undefined
	4.89 undefined
	4.18 undefined
	3.87 undefined
	3.48 undefined
	3.50 undefined
	3.68 undefined

날짜	Altimmune 매출	Altimmune EBIT	Altimmune 이익
2030e	669.3 백만 undefined	818.68 백만 undefined	412.35 백만 undefined
2029e	438.02 백만 undefined	339.03 백만 undefined	278.01 백만 undefined
2028e	270.81 백만 undefined	135.8 백만 undefined	211.79 백만 undefined
2027e	23.91 백만 undefined	-151.95 백만 undefined	-90.67 백만 undefined
2026e	28.86 백만 undefined	-138.39 백만 undefined	-103.21 백만 undefined
2025e	5,686.3 undefined	-111.53 백만 undefined	-94.49 백만 undefined
2024	20,000 undefined	-103.17 백만 undefined	-95.06 백만 undefined
2023	426,000 undefined	-83.51 백만 undefined	-88.45 백만 undefined
2022	-70,000 undefined	-87.74 백만 undefined	-84.71 백만 undefined
2021	4.41 백만 undefined	-85.54 백만 undefined	-97.09 백만 undefined
2020	8.19 백만 undefined	-54.8 백만 undefined	-49.04 백만 undefined
2019	5.8 백만 undefined	-20.46 백만 undefined	-20.97 백만 undefined
2018	10.33 백만 undefined	-17.89 백만 undefined	-42.48 백만 undefined
2017	10.74 백만 undefined	-16.13 백만 undefined	-51.36 백만 undefined
2016	3.24 백만 undefined	-11.09 백만 undefined	-11.46 백만 undefined
2015	10.64 백만 undefined	-800,000 undefined	-3.44 백만 undefined
2014	10.19 백만 undefined	-10.19 백만 undefined	-9.96 백만 undefined
2013	17.91 백만 undefined	-10.84 백만 undefined	-11.72 백만 undefined
2012	25.18 백만 undefined	-6.27 백만 undefined	-4.92 백만 undefined
2011	24.27 백만 undefined	-11.73 백만 undefined	-3.8 백만 undefined
2010	20.99 백만 undefined	-18.91 백만 undefined	-34.85 백만 undefined
2009	27.55 백만 undefined	-25.97 백만 undefined	-32.28 백만 undefined
2008	32.91 백만 undefined	-19.11 백만 undefined	-36.42 백만 undefined
2007	14.64 백만 undefined	-16.51 백만 undefined	-17.72 백만 undefined
2006	1.66 백만 undefined	-14.53 백만 undefined	-21.72 백만 undefined
2005	590,000 undefined	330,000 undefined	280,000 undefined

	매출	EBIT	이익
2005	590,000 USD	330,000 USD	280,000 USD
2006	1.66 백만 USD	-14.53 백만 USD	-21.72 백만 USD
2007	14.64 백만 USD	-16.51 백만 USD	-17.72 백만 USD
2008	32.91 백만 USD	-19.11 백만 USD	-36.42 백만 USD
2009	27.55 백만 USD	-25.97 백만 USD	-32.28 백만 USD
2010	20.99 백만 USD	-18.91 백만 USD	-34.85 백만 USD
2011	24.27 백만 USD	-11.73 백만 USD	-3.8 백만 USD
2012	25.18 백만 USD	-6.27 백만 USD	-4.92 백만 USD
2013	17.91 백만 USD	-10.84 백만 USD	-11.72 백만 USD
2014	10.19 백만 USD	-10.19 백만 USD	-9.96 백만 USD
2015	10.64 백만 USD	-800,000 USD	-3.44 백만 USD
2016	3.24 백만 USD	-11.09 백만 USD	-11.46 백만 USD
2017	10.74 백만 USD	-16.13 백만 USD	-51.36 백만 USD
2018	10.33 백만 USD	-17.89 백만 USD	-42.48 백만 USD
2019	5.8 백만 USD	-20.46 백만 USD	-20.97 백만 USD
2020	8.19 백만 USD	-54.8 백만 USD	-49.04 백만 USD
2021	4.41 백만 USD	-85.54 백만 USD	-97.09 백만 USD
2022	-70,000 USD	-87.74 백만 USD	-84.71 백만 USD
2023	426,000 USD	-83.51 백만 USD	-88.45 백만 USD
2024	20,000 USD	-103.17 백만 USD	-95.06 백만 USD
2025e	5,686.3 USD	-111.53 백만 USD	-94.49 백만 USD
2026e	28.86 백만 USD	-138.39 백만 USD	-103.21 백만 USD
2027e	23.91 백만 USD	-151.95 백만 USD	-90.67 백만 USD
2028e	270.81 백만 USD	135.8 백만 USD	211.79 백만 USD
2029e	438.02 백만 USD	339.03 백만 USD	278.01 백만 USD
2030e	669.3 백만 USD	818.68 백만 USD	412.35 백만 USD

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

1.4	5.1	52.7	22.9	5.8	11.8	11.2	12.7	10.5	18.6	15.6	2.9	8.8	33.7	37.2	215.9	190.3	184.9	197.82	131.89
0	1.5	4	3.8	8.9	9.3	7.4	6.5	3.6	0.4	1.5	0.4	3.8	3.5	1	4.6	0.4	0.2	1.11	0.54
0	0	1.2	6.5	9.8	0	0	0	0	0	0	0.8	6.4	1	0.7	7.8	5.4	2.3	3.74	2.57
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
68.7	1	0.5	12.9	1	2.5	0.9	0.5	0.2	0.2	0.2	0.4	4.5	1.1	0.5	1.9	8	5.4	6.96	2.25
70.1	7.6	58.4	46.1	25.5	23.6	19.5	19.7	14.3	19.2	17.3	4.5	23.5	39.3	39.4	230.2	204.1	192.8	209.63	137.25
0	5.2	6.6	5.3	6.3	1.2	0.8	0.5	0.4	0.3	0.2	0.2	0.6	1.3	1.8	2	2.2	1.7	1.01	2.05
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	1.2	1.3	0.9	0.9	0	0	0	0	0	0	15	38.7	13.9	12.7	12.8	12.4	12.4	0	0
0	0	0	2.5	2.3	2.3	2.3	2.3	2.3	2.3	2.3	18.8	0	0	0	0	0	0	0	0
0	0.7	0.3	1.5	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0	0.2	0.2	0.1	0.1	0.1	0	0	0
0	7.1	8.2	10.2	9.8	3.6	3.2	2.9	2.8	2.7	2.6	34	39.5	15.4	14.6	14.9	14.7	14.1	1.01	2.05
70.1	14.7	66.6	56.3	35.3	27.2	22.7	22.6	17.1	21.9	19.9	38.5	63	54.7	54	245.1	218.8	206.9	210.64	139.31

0	65.4	0	0	0	0	0	0	0	0	0	0	9.3	0	0	0	0	0	0.01	0.01
55.8	0	126.5	142.4	157	200.8	208.5	210.5	217.9	238.8	240.4	71	121.7	170.2	187.9	417.3	497.3	568.4	665.43	689.86
300	-69,900	-87,400	-123,800	-155,000	-189,900	-193,700	-198,600	-210,300	-220,300	-223,700	-31,300	-77,700	-116,900	-137,400	-186,400	-293,200	-377,900	-466,331	-561,390
13.6	0.1	1.5	0.4	1.2	1.3	1	-0.2	-0.2	-0.2	0	-7.6	-4.6	-5	-5	-5	-5	-5.2	-5	-4.97
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
69.7	-4.4	40.6	19	3.2	12.2	15.8	11.7	7.4	18.3	16.7	32.1	48.7	48.3	45.5	225.9	199.1	185.3	194.1	123.51
0	0.8	1.4	3.9	1.9	3.1	1.4	1.7	1.1	0.4	0.5	2	0.1	0.4	0	0.6	2	4.8	2.07	0.21
0.1	1.6	2.9	6.2	9.8	3	2.7	2.3	3.1	1.1	1.5	3	3.6	4.1	3.8	11.4	10.2	11.1	10.07	10.26
0.3	0	0.7	8.4	1.8	0.1	0.5	1.4	0.5	0.4	0.1	0	0	0	0.1	0	6.1	1.2	0	0
0	11.8	0	13.4	0	0	0	1.3	1.1	0	0	0.5	0	0	0	0	0	0	0	0
0	0	4	4	0	0	0	0.8	1	0.7	0	0	0	0.1	0	0	0	0	0	0
0.4	14.2	9	35.9	13.5	6.2	4.6	7.5	6.8	2.6	2.1	5.5	3.7	4.6	3.9	12	18.3	17.1	12.14	10.47
0	0	16.7	0.9	17.4	0	0	1.7	0.7	0	0	0.5	0.6	0.5	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	5.9	0.1	0	0	0	0	0	0
0	2.4	0.4	0.6	1.3	8.8	2.3	1.9	2.3	1.1	1	0.2	4	1.4	4.6	7.2	1.5	4.6	4.4	5.33
0	2.4	17.1	1.5	18.7	8.8	2.3	3.6	3	1.1	1	0.7	10.5	2	4.6	7.2	1.5	4.6	4.4	5.33
0.4	16.6	26.1	37.4	32.2	15	6.9	11.1	9.8	3.7	3.1	6.2	14.2	6.6	8.5	19.2	19.8	21.7	16.54	15.8
70.1	12.2	66.7	56.4	35.4	27.2	22.7	22.8	17.2	22	19.8	38.3	62.9	54.9	54	245.1	218.9	207	210.64	139.31

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0	-15	-13	-36	-32	-34	-3	-4	-11	-9	-3	-11	-46	-39	-20	-49	-97	-84	-88
0	0	0	0	0	1,000	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	-2	-6	0	0	0	0	0
0	0	0	1	-5	-1	0	1	2	0	0	1	-8	6	1	-4	0	14	-8
0	0	0	23	12	22	-2	2	3	2	1	4	38	29	10	21	24	16	20
0	0	0	0	1,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1,000	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-13	-13	-13	-28	-14	-7	-2	-7	-8	-3	-6	-20	-9	-9	-34	-78	-62	-75
0	0	0	0	-1	0	0	0	0	0	0	0	0	-1	0	0	-12	0	0
-68	0	-12	-10	-7	2	1	0	0	0	0	0	13	-1	-28	-72	87	-73	13
-68	0	-12	-9	-6	3	1	0	0	0	0	0	13	0	-28	-71	99	-73	13
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	11	8	-4	0	0	0	3	0	-2	0	0	2	-1	0	0	0	0	0
75	0	0	12	4	21	5	0	6	18	0	5	13	34	12	213	65	56	86
69	11	61	2	18	21	5	3	5	16	0	4	15	32	12	213	65	56	86
-5	0	53	-6	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	-2	35	-20	-17	9	0	1	-2	8	-3	-1	9	22	-25	106	74	-79	24
0.55	-14.32	-14.52	-13.71	-29.18	-15.23	-7.88	-2.32	-7.25	-8.56	-3.31	-6.57	-20.38	-10.41	-9.63	-34.65	-90.55	-62.72	-75.86
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Altimmune 브루토마진	Altimmune 이익 마진	Altimmune EBIT-마진	Altimmune 이익 마진
2030e	100.47 %	122.32 %	61.61 %
2029e	100.47 %	77.4 %	63.47 %
2028e	100.47 %	50.15 %	78.21 %
2027e	100.47 %	-635.61 %	-379.26 %
2026e	100.47 %	-479.51 %	-357.63 %
2025e	100.47 %	-1.96 백만 %	-1.66 백만 %
2024	100.47 %	-515,860 %	-475,295 %
2023	100.47 %	-19,603.29 %	-20,762.21 %
2022	100.47 %	125,342.86 %	121,014.28 %
2021	100.47 %	-1,939.68 %	-2,201.59 %
2020	100.47 %	-669.11 %	-598.78 %
2019	100.47 %	-352.76 %	-361.55 %
2018	100.47 %	-173.18 %	-411.23 %
2017	100.47 %	-150.19 %	-478.21 %
2016	100.47 %	-342.28 %	-353.7 %
2015	100.47 %	-7.52 %	-32.33 %
2014	100.47 %	-100 %	-97.74 %
2013	100.47 %	-60.52 %	-65.44 %
2012	100.47 %	-24.9 %	-19.54 %
2011	100.47 %	-48.33 %	-15.66 %
2010	100.47 %	-90.09 %	-166.03 %
2009	100.47 %	-94.26 %	-117.17 %
2008	100.47 %	-58.07 %	-110.67 %
2007	100.47 %	-112.77 %	-121.04 %
2006	100.47 %	-875.3 %	-1,308.43 %
2005	100.47 %	55.93 %	47.46 %

	브루토마진	EBIT-마진	이익 마진
2005	100.47 %	55.93 %	47.46 %
2006	100.47 %	-875.3 %	-1,308.43 %
2007	100.47 %	-112.77 %	-121.04 %
2008	100.47 %	-58.07 %	-110.67 %
2009	100.47 %	-94.26 %	-117.17 %
2010	100.47 %	-90.09 %	-166.03 %
2011	100.47 %	-48.33 %	-15.66 %
2012	100.47 %	-24.9 %	-19.54 %
2013	100.47 %	-60.52 %	-65.44 %
2014	100.47 %	-100 %	-97.74 %
2015	100.47 %	-7.52 %	-32.33 %
2016	100.47 %	-342.28 %	-353.7 %
2017	100.47 %	-150.19 %	-478.21 %
2018	100.47 %	-173.18 %	-411.23 %
2019	100.47 %	-352.76 %	-361.55 %
2020	100.47 %	-669.11 %	-598.78 %
2021	100.47 %	-1,939.68 %	-2,201.59 %
2022	100.47 %	125,342.86 %	121,014.28 %
2023	100.47 %	-19,603.29 %	-20,762.21 %
2024	100.47 %	-515,860 %	-475,295 %
2025e	100.47 %	-1.96 백만 %	-1.66 백만 %
2026e	100.47 %	-479.51 %	-357.63 %
2027e	100.47 %	-635.61 %	-379.26 %
2028e	100.47 %	50.15 %	78.21 %
2029e	100.47 %	77.4 %	63.47 %
2030e	100.47 %	122.32 %	61.61 %

날짜	Altimmune 주당 매출	Altimmune EBIT 당 주식	Altimmune 주당 이익
2030e	9.43 undefined	0 undefined	5.81 undefined
2029e	6.17 undefined	0 undefined	3.92 undefined
2028e	3.81 undefined	0 undefined	2.98 undefined
2027e	0.34 undefined	0 undefined	-1.28 undefined
2026e	0.41 undefined	0 undefined	-1.45 undefined
2025e	0 undefined	0 undefined	-1.33 undefined
2024	0 undefined	-1.45 undefined	-1.34 undefined
2023	0.01 undefined	-1.57 undefined	-1.66 undefined
2022	-0 undefined	-1.87 undefined	-1.81 undefined
2021	0.11 undefined	-2.07 undefined	-2.35 undefined
2020	0.32 undefined	-2.14 undefined	-1.91 undefined
2019	0.44 undefined	-1.56 undefined	-1.6 undefined
2018	3.69 undefined	-6.39 undefined	-15.17 undefined
2017	24.98 undefined	-37.51 undefined	-119.44 undefined
2016	14.09 undefined	-48.22 undefined	-49.83 undefined
2015	50.67 undefined	-3.81 undefined	-16.38 undefined
2014	53.63 undefined	-53.63 undefined	-52.42 undefined
2013	105.35 undefined	-63.76 undefined	-68.94 undefined
2012	157.38 undefined	-39.19 undefined	-30.75 undefined
2011	151.69 undefined	-73.31 undefined	-23.75 undefined
2010	190.82 undefined	-171.91 undefined	-316.82 undefined
2009	306.11 undefined	-288.56 undefined	-358.67 undefined
2008	411.38 undefined	-238.88 undefined	-455.25 undefined
2007	488 undefined	-550.33 undefined	-590.67 undefined
2006	0 undefined	0 undefined	0 undefined
2005	0 undefined	0 undefined	0 undefined

	주당 매출	EBIT 당 주식	주당 이익
2005	0 USD	0 USD	0 USD
2006	0 USD	0 USD	0 USD
2007	488 USD	-550.33 USD	-590.67 USD
2008	411.38 USD	-238.88 USD	-455.25 USD
2009	306.11 USD	-288.56 USD	-358.67 USD
2010	190.82 USD	-171.91 USD	-316.82 USD
2011	151.69 USD	-73.31 USD	-23.75 USD
2012	157.38 USD	-39.19 USD	-30.75 USD
2013	105.35 USD	-63.76 USD	-68.94 USD
2014	53.63 USD	-53.63 USD	-52.42 USD
2015	50.67 USD	-3.81 USD	-16.38 USD
2016	14.09 USD	-48.22 USD	-49.83 USD
2017	24.98 USD	-37.51 USD	-119.44 USD
2018	3.69 USD	-6.39 USD	-15.17 USD
2019	0.44 USD	-1.56 USD	-1.6 USD
2020	0.32 USD	-2.14 USD	-1.91 USD
2021	0.11 USD	-2.07 USD	-2.35 USD
2022	-0 USD	-1.87 USD	-1.81 USD
2023	0.01 USD	-1.57 USD	-1.66 USD
2024	0 USD	-1.45 USD	-1.34 USD
2025e	0 USD	0 USD	-1.33 USD
2026e	0.41 USD	0 USD	-1.45 USD
2027e	0.34 USD	0 USD	-1.28 USD
2028e	3.81 USD	0 USD	2.98 USD
2029e	6.17 USD	0 USD	3.92 USD
2030e	9.43 USD	0 USD	5.81 USD

	주식 수량
2005	0 Aktien
2006	0 Aktien
2007	30,000 Aktien
2008	80,000 Aktien
2009	90,000 Aktien
2010	110,000 Aktien
2011	160,000 Aktien
2012	160,000 Aktien
2013	170,000 Aktien
2014	190,000 Aktien
2015	210,000 Aktien
2016	230,000 Aktien
2017	430,000 Aktien
2018	2.8 백만 Aktien
2019	13.12 백만 Aktien
2020	25.64 백만 Aktien
2021	41.28 백만 Aktien
2022	46.93 백만 Aktien
2023	53.25 백만 Aktien
2024	71 백만 Aktien
2025e	71 백만 Aktien
2026e	71 백만 Aktien
2027e	71 백만 Aktien
2028e	71 백만 Aktien
2029e	71 백만 Aktien
2030e	71 백만 Aktien

날짜	Altimmune 배당금
2017	873 undefined

	배당금	배당금 (추정)
2005	0 USD	0 USD
2006	0 USD	0 USD
2007	0 USD	0 USD
2008	0 USD	0 USD
2009	0 USD	0 USD
2010	0 USD	0 USD
2011	0 USD	0 USD
2012	0 USD	0 USD
2013	0 USD	0 USD
2014	0 USD	0 USD
2015	0 USD	0 USD
2016	0 USD	0 USD
2017	873 USD	0 USD
2018	0 USD	0 USD
2019	0 USD	0 USD
2020	0 USD	0 USD
2021	0 USD	0 USD
2022	0 USD	0 USD
2023	0 USD	0 USD
2024	0 USD	0 USD
2025e	0 USD	0 USD
2026e	0 USD	0 USD
2027e	0 USD	0 USD
2028e	0 USD	0 USD
2029e	0 USD	0 USD
2030e	0 USD	0 USD

날짜	Altimmune 배당률
2030e	0 %
2029e	0 %
2028e	0 %
2027e	0 %
2026e	0 %
2025e	0 %
2024	0 %
2023	0 %
2022	0 %
2021	0 %
2020	0 %
2019	0 %
2018	0 %
2017	-730.91 %
2016	0 %
2015	0 %
2014	0 %
2013	0 %
2012	0 %
2011	0 %
2010	0 %
2009	0 %
2008	0 %
2007	0 %
2006	0 %
2005	0 %

	배당률
2005	0 %
2006	0 %
2007	0 %
2008	0 %
2009	0 %
2010	0 %
2011	0 %
2012	0 %
2013	0 %
2014	0 %
2015	0 %
2016	0 %
2017	-730.91 %
2018	0 %
2019	0 %
2020	0 %
2021	0 %
2022	0 %
2023	0 %
2024	0 %
2025e	0 %
2026e	0 %
2027e	0 %
2028e	0 %
2029e	0 %
2030e	0 %

EPS-예상치	EPS-실제	보고 분기
-0.37	-0.26 (29.12 %)	2025 Q1
-0.33	-0.33 (0.21 %)	2024 Q4
-0.36	-0.32 (10.46 %)	2024 Q3
-0.34	-0.35 (-1.63 %)	2024 Q2
-0.37	-0.34 (8.31 %)	2024 Q1
-0.44	-0.33 (24.64 %)	2023 Q4
-0.43	-0.39 (9.05 %)	2023 Q3
-0.47	-0.32 (31.8 %)	2023 Q2
-0.48	-0.4 (17.41 %)	2023 Q1
-0.51	-0.43 (15.09 %)	2022 Q4
-0.51	-0.48 (5.9 %)	2022 Q3
-0.48	-0.42 (12.45 %)	2022 Q2
-0.59	-0.44 (25.54 %)	2022 Q1
-0.65	-0.57 (12.95 %)	2021 Q4
-0.4	-0.81 (-103.88 %)	2021 Q3
-0.51	-0.6 (-17.62 %)	2021 Q2
-0.48	-0.38 (20.62 %)	2021 Q1
-0.76	-0.17 (77.62 %)	2020 Q4
-0.77	-0.54 (29.65 %)	2020 Q3
-0.4	-0.94 (-132.67 %)	2020 Q2
-0.32	-0.26 (19.55 %)	2020 Q1
-0.26	-0.25 (4.8 %)	2019 Q4
-0.19	-0.73 (-280.41 %)	2019 Q3
-0.25	-0.26 (-2.97 %)	2019 Q2
-3.64	-2.34 (35.64 %)	2018 Q3
-4.55	-4.8 (-5.61 %)	2018 Q2
-15.15	-7.5 (50.5 %)	2018 Q1
-15.15	-17.4 (-14.85 %)	2017 Q4
-8.48	-10.2 (-20.23 %)	2017 Q3
-7.58	-24 (-216.83 %)	2014 Q3
-16.67	-3 (82 %)	2014 Q2
-18.18	-12 (33.99 %)	2014 Q1
-15.15	-24 (-58.42 %)	2013 Q4
-10.61	-24 (-126.31 %)	2013 Q3
-9.09	-6 (33.99 %)	2013 Q2
-15.15	-12 (20.79 %)	2013 Q1
-12.12	-6 (50.5 %)	2012 Q4
-9.09	0 (100 %)	2012 Q3
-9.09	-6 (33.99 %)	2012 Q2
-15.15	-18 (-18.81 %)	2012 Q1
-32.32	3 (109.28 %)	2011 Q4
-25.25	0 (100 %)	2011 Q3
-31.82	-15 (52.85 %)	2011 Q2
-29.29	-12 (59.03 %)	2011 Q1
-26.26	-138 (-425.49 %)	2010 Q4
-52.52	-42 (20.03 %)	2010 Q3
-62.12	-66 (-6.25 %)	2010 Q2
-51.51	-84 (-63.08 %)	2010 Q1
-62.12	-60 (3.41 %)	2009 Q4
-57.57	-150 (-160.55 %)	2009 Q3
-54.54	-72 (-32.01 %)	2009 Q2
-60.6	-69 (-13.86 %)	2009 Q1
-78.78	-51 (35.26 %)	2008 Q4
-78.78	-60 (23.84 %)	2008 Q3

%-지분	이름	주식	변경
7.78924 %	BlackRock Institutional Trust Company, N.A.	5,530,623	-133,001
6.18952 %	The Vanguard Group, Inc.	4,394,769	-24,150
4.77663 %	State Street Global Advisors (US)	3,391,571	-78,446
3.87305 %	Tang Capital Management, LLC	2,750,000	0
2.40254 %	Geode Capital Management, L.L.C.	1,705,885	47,379
1.98880 %	Two Sigma Investments, LP	1,412,116	741,113
1.86560 %	Columbia Threadneedle Investments (UK)	1,324,639	-3,776,024
1.64547 %	Marshall Wace LLP	1,168,338	1,102,821
1.57954 %	Knoll Capital Management, LLC	1,121,524	0
1.56513 %	Millennium Management LLC	1,111,299	765,662
1.51551 %	Susquehanna International Group, LLP	1,076,064	575,145
1.48837 %	Bellevue Asset Management AG	1,056,793	111,347
1.35470 %	Schroder Investment Management Ltd. (SIM)	961,884	533,563
1.02553 %	UBS Financial Services, Inc.	728,163	80,108
0.83651 %	Northern Trust Investments, Inc.	593,954	-39,186
0.69359 %	Dimensional Fund Advisors, L.P.	492,469	-140,972
0.50009 %	Garg (Vipin K)	355,082	19,982
0.47802 %	Morgan Stanley & Co. LLC	339,410	90,949
0.45688 %	RFG Advisory, LLC	324,397	324,397
0.41471 %	Beirne Wealth Consulting Services, LLC	294,458	0
0.40454 %	BlackRock Financial Management, Inc.	287,239	92,495
0.39685 %	Gerber LLC	281,778	0
0.39512 %	BofA Global Research (US)	280,552	98,663
0.36664 %	Morgan Stanley Smith Barney LLC	260,329	7,884
0.36141 %	Group One Trading, L.P.	256,610	-21,925
0.31682 %	Wellington Management Company, LLP	224,954	19,721
0.30328 %	Nuveen LLC	215,340	0
0.29841 %	Charles Schwab Investment Management, Inc.	211,879	0
0.29581 %	Goldman Sachs & Company, Inc.	210,036	-186,719
0.27841 %	Hennion & Walsh Asset Management, Inc.	197,684	-7,906
0.27624 %	BlackRock Investment Management, LLC	196,143	-2,325
0.26402 %	Barclays Bank PLC	187,462	29,934
0.26333 %	Federated MDTA LLC	186,971	186,971
0.25393 %	Goldman Sachs Asset Management, L.P.	180,299	50,884
0.23030 %	Citi Investment Research (US)	163,518	38,828
0.21634 %	Exchange Traded Concepts, LLC	153,606	-5,967
0.21498 %	Jane Street Capital, L.L.C.	152,642	-126,008
0.21126 %	Lynwood Capital Management Inc.	150,000	150,000
0.21014 %	Steward Partners Investment Advisory, LLC	149,209	121,159
0.20334 %	BNY Mellon Asset Management	144,379	2,212
0.20235 %	Rafferty Asset Management LLC	143,672	-14,078
0.19647 %	Schweizerische Nationalbank	139,500	0
0.18856 %	Squarepoint Capital LLP	133,885	119,179
0.16617 %	Summit Financial Wealth Advisors, Llc	117,988	18,500
0.15002 %	Rhumbline Advisers Ltd. Partnership	106,519	1,643
0.14646 %	Columbia Threadneedle Investments (US)	103,991	-34,399
0.14577 %	Silvercrest Asset Management Group LLC	103,500	0
0.14087 %	Brown Wealth Management, LLC.	100,024	50,024
0.14084 %	Macquarie Investment Management	100,000	0
0.12675 %	Hanwha Asset Management Co., Ltd.	90,000	90,000
0.12630 %	Commonwealth Financial Network	89,676	3,582
0.12394 %	Sculptor Capital Management, Inc	88,000	88,000
0.12287 %	BlackRock Advisors (UK) Limited	87,240	0
0.11733 %	IMC Chicago, LLC	83,311	-220,221
0.11125 %	BlackRock Asset Management Ireland Limited	78,991	19,408
0.11072 %	MML Investors Services, LLC	78,613	-30,762
0.10394 %	DWS Investments UK Limited	73,803	72
0.10312 %	Roberts (M Scot)	73,220	9,809
0.10177 %	HSBC Global Asset Management (UK) Limited	72,258	72,258
0.10107 %	AllianceBernstein L.P.	71,760	0
0.10057 %	INTECH Investment Management LLC	71,408	25,285
0.09859 %	Abaris Investment Management AG	70,000	-75,000
0.09591 %	Legal & General Investment Management Ltd.	68,102	0
0.09377 %	LPL Financial LLC	66,581	8,408
0.09355 %	California State Teachers Retirement System	66,422	0
0.08835 %	J.P. Morgan Securities plc	62,734	193
0.08451 %	UBS Switzerland AG	60,002	-11,498
0.08371 %	Baird Trust Company LLC	59,440	0
0.08110 %	UBS Asset Management (Switzerland)	57,584	8,688
0.07739 %	Balyasny Asset Management LP	54,953	-141,374
0.07574 %	Wells Fargo Advisors	53,781	-124,694
0.07250 %	Mirae Asset Global Investments (USA) LLC	51,478	2,448
0.07115 %	D. E. Shaw & Co., L.P.	50,516	-409,317
0.06772 %	State of Wisconsin Investment Board	48,087	-520
0.06609 %	RBC Capital Markets Wealth Management	46,927	302
0.06601 %	MetLife Investment Management, LLC	46,870	2,396
0.06377 %	UBS Fund Management (Switzerland) AG	45,278	1,782
0.06339 %	Eisenstadt (Richard I)	45,012	11,721
0.06338 %	Deka Investment GmbH	45,000	45,000
0.06284 %	Mellon Investments Corporation	44,621	-50
0.06169 %	Brevan Howard Capital Management LP	43,804	29,773
0.05897 %	Invesco Advisers, Inc.	41,872	16,070
0.05850 %	Harvest Fund Management Co., Ltd.	41,534	3,327
0.05772 %	OP Varainhoito Oy	40,986	40,986
0.05764 %	ExodusPoint Capital Management, LP	40,927	40,927
0.05634 %	FIDE Capital	40,000	0
0.05529 %	Invesco Capital Management LLC	39,256	-182,028
0.05474 %	Caption Management, LLC	38,864	38,864
0.05380 %	Fox Run Management, L.L.C	38,200	25,295
0.05338 %	Wells Fargo Bank, N.A.	37,900	837
0.05141 %	Stifel, Nicolaus & Company, Incorporated	36,500	23,397
0.04941 %	Kraematon Investment Advisors, Inc	35,085	4,300
0.04916 %	Jordt (Raymond M)	34,902	20,242
0.04901 %	Corebridge Financial Inc.	34,796	-516
0.04731 %	JPMorgan Private Bank (United States)	33,589	2,356
0.04507 %	Janus Henderson Investors	32,000	0
0.04451 %	Creative Planning, Inc.	31,606	-5,392
0.04444 %	Morgan Stanley & Co. International Plc	31,556	1,234
0.04433 %	T. Rowe Price International Ltd	31,478	3,332
0.04345 %	Wealth Effects LLC	30,850	-2,000

What values and corporate philosophy does Altimmune represent?

Altimmune Inc represents a core value of innovation and commitment to transformative medical solutions. With a strong corporate philosophy focused on advancing novel therapies, Altimmune Inc continuously strives to improve patient outcomes through groundbreaking immunotherapies. The company's dedication to scientific excellence and rigorous research enables the development of cutting-edge vaccine candidates, including intranasal vaccines to combat infectious diseases. Altimmune Inc's vision encompasses pioneering approaches in immunology and the goal of addressing unmet medical needs worldwide. By leveraging its expertise, Altimmune Inc remains at the forefront of medical advancements, exemplifying a steadfast commitment to improving global health.

In which countries and regions is Altimmune primarily present?

Altimmune Inc is primarily present in the United States.

What significant milestones has the company Altimmune achieved?

Altimmune Inc has achieved significant milestones in its journey. Some noteworthy accomplishments include the successful completion of Phase 2 clinical trials for its lead product candidate, AdCOVID, a single-dose intranasal COVID-19 vaccine. The company has also demonstrated the effectiveness of NasoShield, a vaccine for anthrax, in preclinical studies. Altimmune Inc has further enhanced its portfolio by acquiring Spitfire Pharma, a biopharmaceutical company focused on liver diseases. Additionally, the company has established collaborations with leading organizations, including the University of Alabama and the National Institutes of Health, to advance its innovative pipeline. These milestones highlight Altimmune Inc's dedication to advancing novel therapies and its potential for future growth in the biopharmaceutical industry.

What is the history and background of the company Altimmune?

Altimmune Inc is a biopharmaceutical company focused on developing and commercializing immunotherapeutic products. Founded in 1997, Altimmune has a rich history of innovation in the field of immunology. The company specializes in the development of novel vaccines and immune-modulating therapies to combat infectious diseases. Altimmune's proprietary platform technologies enable the rapid design and development of next-generation immunotherapies. With a strong commitment to scientific research and development, Altimmune aims to transform the treatment landscape by addressing unmet medical needs. With its experienced team and extensive portfolio, Altimmune Inc is poised to make a significant impact on the global healthcare industry.

Who are the main competitors of Altimmune in the market?

The main competitors of Altimmune Inc in the market include companies such as Inovio Pharmaceuticals, VBI Vaccines, Novavax, and Moderna Inc.

In which industries is Altimmune primarily active?

Altimmune Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Altimmune?

Altimmune Inc is a biopharmaceutical company with a business model focused on developing and commercializing novel immunotherapeutic products. The company aims to address various diseases and medical conditions through innovative vaccine technologies and immune modulation platforms. Altimmune Inc is committed to advancing its proprietary pipeline, leveraging its expertise in immunology and vaccine development. With a strong emphasis on research and development, Altimmune Inc strives to bring novel treatments to market that can positively impact the lives of patients worldwide.

Altimmune 2025의 P/E 비율은 얼마입니까?

Altimmune의 P/E 비율은 -3.07입니다.

Altimmune 2025의 KUV는 얼마입니까?

Altimmune의 P/S 비율은 50,958.42입니다.

Altimmune의 AlleAktien 품질 점수는 얼마인가요?

Altimmune에 대한 AlleAktien 품질 점수는 3/10입니다.

Altimmune 2025의 매출은 얼마인가요?

예상되는 Altimmune 매출은 5,686.3 USD입니다.

Altimmune 2025의 이익은 얼마인가요?

예상되는 Altimmune 이익은 -94.49 백만 USD입니다.

Altimmune은 무엇을 하나요?

The company Altimmune Inc. is a biopharmaceutical company specializing in the development of immunotherapies and vaccines for various diseases. Its business model is based on innovative research and development to meet the increasingly complex challenges of the medical industry. The company operates in three business areas - Immundevelopment, Vaxine, and Altimmune UK. Immundevelopment focuses on the research of immunotherapies and viral infections such as hepatitis B, HIV, and influenza. Vaxine develops vaccines against flu, anthrax, MERS, RSV, and COVID-19. Altimmune UK is increasingly focused on the field of neuroscience and oncology. Altimmune is divided into two pillars, immunotherapy and vaccine development. The two pillars work closely together to accelerate and improve the development of therapies and vaccines. In the immunotherapy pillar, treatments are being researched that stimulate the immune system to fight against various diseases. In the vaccine development, Altimmune produces vaccines that induce active immunization against certain diseases. One of Altimmune's most important products is NasoVAX, an intranasally administered flu vaccine. Compared to conventional injectable vaccines, NasoVAX offers faster action and does not require a nurse. NasoShield, an intranasally administered anthrax vaccine, is another well-known product from Altimmune. The company has also developed COVID-19 vaccine candidates that are now being tested in clinical trials. Altimmune aims to develop innovative solutions for serious diseases. The company has a strong commitment to research and development and is committed to continuing its successes in drug development. The company's mission is to ensure the creation of cost-effective solutions and improvement of outcomes for patients. Through the development of novel therapies and vaccines, Altimmune is repeatedly praised as one of the most promising companies in the industry. With a growing product range and a strong research and development department, the company is well-equipped to tackle important medical challenges of the future. In the future, it will be of great importance for Altimmune to continue developing innovative products that meet medical requirements. The industry will evolve through new scientific discoveries and the use of cutting-edge technologies, and Altimmune strives to play a leading role in this transformation.

Altimmune 배당금은 얼마입니까?

Altimmune은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Altimmune이 얼마나 자주 배당을 지급하나요?

Altimmune의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Altimmune ISIN이 무엇입니까?

Altimmune의 ISIN은 US02155H2004입니다.

Altimmune WKN은 무엇인가요?

Altimmune의 WKN은 A2N5Z6입니다.

Altimmune 티커는 무엇인가요?

Altimmune의 티커는 ALT입니다.

Altimmune이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Altimmune은(는) 873 USD 의 배당금을 지급했습니다. 이는 약 21,391.82 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Altimmune은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Altimmune의 배당 수익률은 얼마입니까?

Altimmune의 현재 배당 수익률은 21,391.82 %입니다.

Altimmune의 배당금은 언제 지급되나요?

Altimmune은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Altimmune의 배당금은 얼마나 안전한가요?

Altimmune은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Altimmune의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Altimmune이(가) 속해 있는 섹터는 어디인가요?

Altimmune은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Altimmune kaufen, um die vorherige Dividende zu erhalten?

Altimmune의 마지막 배당금을 2.91 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Altimmune의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Altimmune의 2024년도 배당금은 얼마였습니까?

2024년에 Altimmune는 0 USD를 배당금으로 지급했습니다.

Altimmune는 어떤 화폐로 배당금을 지급하나요?

Altimmune의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	Altimmune 티커
뒤셀도르프	3G0.DU
프랑크푸르트	3G0.F
LONDON	0A4C.L
뮌헨	3G0.MU
NASDAQ	ALT

Altimmune 티커	Altimmune FIGI
ALT:US	BBG000FXML90
ALT:UA	BBG000FXMM70
ALT:UC	BBG000FXMML4
ALT:UN	BBG000FXNQF1
ALT:UP	BBG000FXNR87
ALT:UQ	BBG000FXNRP8
ALT:UB	BBG000FXNS85
ALT:UM	BBG000FXNV06
ALT:UX	BBG000FXNWR5
ALT:UD	BBG000FXP1Y3
ALT:UF	BBG000FXP4J4
ALT:VY	BBG000FXP547
ALT:VJ	BBG000FXP5T0
ALT:VK	BBG000FXP6B7
3G0:GR	BBG00D6Q7H84
3G0:GF	BBG00D6Q7H93
3G0:GD	BBG00D6Q7HB0
3G0:GS	BBG00D6Q7HD8
3G0:GM	BBG00D6Q7HF6
3G0:GB	BBG00D6Q7HG5
PIPEUR:EO	BBG00D6TSY79
PIPEUR:XH	BBG00D6TSYB4
PIPEUR:XF	BBG00D6TSYD2
PIPEUR:XE	BBG00D6TSYG9
PIPEUR:XJ	BBG00D6TSYH8
PIPEUR:XL	BBG00D6TSYJ6
PIPEUR:XG	BBG00D6TSYK4
PIPEUR:XO	BBG00D6TSYL3
PIPEUR:XS	BBG00D6TSYQ8
PIPEUR:XA	BBG00D6TSYR7
PIPEUR:E1	BBG00D6TSYS6
PIPEUR:XT	BBG00D6TSYT5
PIPEUR:XW	BBG00D6TSYV2
PIPEUR:XU	BBG00D6TSYW1
PIPEUR:XV	BBG00D6TSYX0
PIPEUR:EU	BBG00D6TSYZ8
ALT:VF	BBG00DJGC6D4
PIPEUR:XX	BBG00JN8J0H6
PIPUSD:X2	BBG00JX7FBL2
PIPUSD:XB	BBG00JX7FBM1
PIPUSD:XH	BBG00JX7FBP8
PIPUSD:XF	BBG00JX7FBS5
PIPUSD:XE	BBG00JX7FBV1
PIPUSD:XJ	BBG00JX7FBW0
PIPUSD:XL	BBG00JX7FBX9
PIPUSD:XG	BBG00JX7FBY8
PIPUSD:XO	BBG00JX7FBZ7
PIPUSD:XS	BBG00JX7FC30
PIPUSD:XA	BBG00JX7FC49
PIPUSD:E1	BBG00JX7FC58
PIPUSD:XT	BBG00JX7FC67
PIPUSD:XW	BBG00JX7FC76
PIPUSD:XU	BBG00JX7FC85
PIPUSD:XV	BBG00JX7FC94
PIPUSD:XM	BBG00JX7FCB1
PIPUSD:XQ	BBG00JX7FCD9
PIPUSD:XX	BBG00JX7FCF7
PIPUSD:XZ	BBG00JX7FCG6
PIPUSD:EU	BBG00JX7FCJ3
PIPGBP:XS	BBG00L088XY7
PIPGBP:XH	BBG00L088Y11
PIPGBP:XF	BBG00L088Y39
PIPGBP:XE	BBG00L088Y57
PIPGBP:XJ	BBG00L088Y66
PIPGBP:XL	BBG00L088Y75
PIPGBP:XG	BBG00L088Y84
PIPGBP:XO	BBG00L088Y93
PIPGBP:XA	BBG00L088YF6
PIPGBP:E1	BBG00L088YG5
PIPGBP:XT	BBG00L088YH4
PIPGBP:XW	BBG00L088YJ2
PIPGBP:XU	BBG00L088YK0
PIPGBP:XV	BBG00L088YL9
PIPGBP:XM	BBG00L088YM8
PIPGBP:XQ	BBG00L088YP5
PIPGBP:XX	BBG00L088YQ4
PIPGBP:XZ	BBG00L088YR3
PIPGBP:EU	BBG00L088YX6
3G0:GZ	BBG00M0M4J33
3G0:TH	BBG00N74KBC3
3G0:QT	BBG00WS67DH1
PIPEUR:EP	BBG00WS6SKP3
PIPEUR:EZ	BBG00WS6SKT9
ALT:VG	BBG00X1NN839
ALT:VP	BBG00X1S2S46
0A4C:LN	BBG00X940WQ0
PIPGBP:EP	BBG00XCC9TL1
PIPGBP:EZ	BBG00XCC9TN9
ALT1*:MM	BBG00Z6DKQZ9
ALT1*:MF	BBG00Z6DKR05
3G0:LA	BBG018H9GLT8
3G0:LU	BBG018J33MK0

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
0	1	14	32	27	20	24	25	17	10	10	3	10	10	5	8	4	0	0	0	0	28	23	270	438	669
-	-	1,300.00	128.57	-15.63	-25.93	20.00	4.17	-32.00	-41.18	-	-70.00	233.33	-	-50.00	60.00	-50.00	-	-	-	-	-	-17.86	1,073.91	62.22	52.74
-	1,000.00	71.43	31.25	37.04	50.00	41.67	40.00	58.82	100.00	100.00	333.33	100.00	100.00	200.00	125.00	250.00	-	-	-	-	35.71	43.48	3.70	2.28	1.49
0	0	0	0	0	0	0	0	0	0	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-21	-17	-36	-32	-34	-3	-4	-11	-9	-3	-11	-51	-42	-20	-49	-97	-84	-88	-95	-94	-103	-90	211	278	412
-	-	-19.05	111.76	-11.11	6.25	-91.18	33.33	175.00	-18.18	-66.67	266.67	363.64	-17.65	-52.38	145.00	97.96	-13.40	4.76	7.95	-1.05	9.57	-12.62	-334.44	31.75	48.20
0	0	0.03	0.08	0.09	0.11	0.16	0.16	0.17	0.19	0.21	0.23	0.43	2.8	13.12	25.64	41.28	46.93	53.25	71	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Professional-grade financial intelligence

Altimmune 주식 ALT주식과 주식 분석 Altimmune ariva, Altimmune onvista, Altimmune finanzen.net, Altimmune aktienfinder, Altimmune marketscreener, Altimmune marketwatch, Altimmune bloomberg, Altimmune handelsblatt, Altimmune wiwo, Altimmune forum

가격

가격

티커ALT

ISINUS02155H2004

WKNA2N5Z6

Altimmune 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Altimmune 주가 이력

Altimmune 주식 매출, EBIT, 이익 US02155H2004 · A2N5Z6

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Altimmune 매출, 이익 및 EBIT 역사

Altimmune 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Altimmune 주식 마진 US02155H2004 · A2N5Z6

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Altimmune 마진 역사

Altimmune 주식 매출, EBIT, 주당 순이익 US02155H2004 · A2N5Z6

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Altimmune 매출, 이익 및 EBIT 주당 역사

Altimmune 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

Altimmune Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Altimmune 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Altimmune 주식 수량 US02155H2004 · A2N5Z6

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Altimmune 주식 분할

Altimmune 주식 배당금 US02155H2004 · A2N5Z6

배당금

배당금에 대한 개요

해석 및 사용

투자 전략

Altimmune 배당금 내역

Altimmune 주식 배당률 US02155H2004 · A2N5Z6

배당비율

연간 배당비율이란 무엇인가요?

Altimmune 주식 ALT
주식과 주식 분석 Altimmune ariva, Altimmune onvista, Altimmune finanzen.net, Altimmune aktienfinder, Altimmune marketscreener, Altimmune marketwatch, Altimmune bloomberg, Altimmune handelsblatt, Altimmune wiwo, Altimmune forum

티커
ALT

ISIN
US02155H2004

WKN
A2N5Z6